Skip to main content

Ryan Arthur F's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Feb 2, 2022

Accession no.
0001708138-22-000012
Filed
Feb 2, 2022
Trade date
Feb 1, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 12 non-derivative transactions. Open-market sales total $60.7K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ryan Arthur FCIK 0001187443Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 1, 2022Common StockSSaleDisposed−2$600.89−$1,201.7822,580Direct
Feb 1, 2022Common StockSSaleDisposed−1$601.79−$601.7922,579Direct
Feb 1, 2022Common StockSSaleDisposed−13$602.35F2−$7,830.5522,566Direct
Feb 1, 2022Common StockSSaleDisposed−6$603.61F3−$3,621.6622,560Direct
Feb 1, 2022Common StockSSaleDisposed−1$604.26−$604.2622,559Direct
Feb 1, 2022Common StockSSaleDisposed−7$605.50F4−$4,238.522,552Direct
Feb 1, 2022Common StockSSaleDisposed−20$606.74F5−$12,134.822,532Direct
Feb 1, 2022Common StockSSaleDisposed−3$607.56F6−$1,822.6822,529Direct
Feb 1, 2022Common StockSSaleDisposed−1$608.74−$608.7422,528Direct
Feb 1, 2022Common StockSSaleDisposed−36$609.50F7−$21,94222,492Direct
Feb 1, 2022Common StockSSaleDisposed−5$610.17F8−$3,050.8522,487Direct
Feb 1, 2022Common StockSSaleDisposed−5$611.33F9−$3,056.6522,482Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 13 shares of Company stock on February 1, 2022 at prices ranging from $602.09 to $602.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 6 shares of Company stock on February 1, 2022 at prices ranging from $603.06 to $603.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 7 shares of Company stock on February 1, 2022 at prices ranging from $605.19 to $605.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 20 shares of Company stock on February 1, 2022 at prices ranging from $606.07 to $606.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2022 at prices ranging from $607.46 to $607.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 36 shares of Company stock on February 1, 2022 at prices ranging from $609.00 to $609.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F8

Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2022 at prices ranging from $610.02 to $610.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

F9

Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2022 at prices ranging from $611.06 to $611.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)